BeOne Medicines
Company snapshot
A focused view of current company value and the latest reported operating results.
Price history
Five years of adjusted closing-price history for this listing, shown as historical context rather than a live quote.
About this price history
The chart uses the market provider's adjusted daily close for the current listing. It does not stitch predecessor listings and does not represent total return, benchmark performance, or historical valuation.
Operating snapshot
The Analysis tab contains the full deterministic margin and annual-growth view.
Financial performance
Results explorer
Start with annual trends, then switch to normalized quarterly, trailing-twelve-month, or annual result tables.
| Metric | Q2 · Jun 30, 2026 | Q1 · Mar 31, 2026 | Q4 · Dec 31, 2025 | Q3 · Sep 30, 2025 | Q2 · Jun 30, 2025 | Q1 · Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.5B | $1.5B | $1.4B | $1.3B | $1.1B |
| Operating income | $325M | $249.9M | $185M | $163.1M | $87.9M | $11.1M |
| Net income | $237M | $227.4M | $66.5M | $124.8M | $94.3M | $1.3M |
| Operating cash flow | $462.8M | $201.3M | $417.3M | $402.6M | $263.6M | $44.1M |
| Capital expenditures | $27.5M | $40.8M | $37.5M | $48.1M | $43.8M | $56.4M |
| Free cash flow | $435.3M | $160.5M | $379.8M | $354.5M | $219.8M | -$12.3M |
| Metric | TTM · Jun 30, 2026 | TTM · Mar 31, 2026 | TTM · Dec 31, 2025 | TTM · Sep 30, 2025 |
|---|---|---|---|---|
| Revenue | $6.1B | $5.7B | $5.3B | $5B |
| Operating income | $923.1M | $685.9M | $447.1M | $182.7M |
| Net income | $655.7M | $513M | $286.9M | $68.6M |
| Operating cash flow | $1.5B | $1.3B | $1.1B | $785.4M |
| Capital expenditures | $153.9M | $170.2M | $185.8M | $240.8M |
| Free cash flow | $1.3B | $1.1B | $941.7M | $544.6M |
| Metric | Year · Dec 31, 2025 | Year · Dec 31, 2024 | Year · Dec 31, 2023 | Year · Dec 31, 2022 | Year · Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.3B | $3.8B | $2.5B | $1.4B | $1.2B |
| Operating income | $447.1M | -$568.2M | -$1.2B | -$1.8B | -$1.4B |
| Net income | $286.9M | -$644.8M | -$881.7M | -$2B | -$1.5B |
| Operating cash flow | $1.1B | -$140.6M | -$1.2B | -$1.5B | -$1.3B |
| Capital expenditures | $185.8M | $492.7M | $561.9M | $325.4M | $262.9M |
| Free cash flow | $941.7M | -$633.3M | -$1.7B | -$1.8B | -$1.6B |
Reported-period calculation notes
- Some quarterly flow values are calculated from year-to-date figures reported in successive quarterly filings.
- Some fourth-quarter flow values are calculated from the annual total less the reported nine-month total.
Financial position
Valuation
Methodology & freshness
Closing price is a regular-session daily close, not a live quote.
Statistics
A compact key-metrics view of supported financial, valuation, balance-sheet, cash-flow, capital-return, and market facts. Relevant market, historical-window, and reporting dates stay attached to each figure.
Deterministic margins and annual growth rates already derived from validated reported financials.
Latest supported balance-sheet facts plus reviewed debt and liquidity measures where available.
Latest supported operating cash flow, capital spending, free cash flow, dividends, and repurchases.
Financial analysis
Margins and growth rates are calculated from the reported financial results shown on this page.